Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.71 |
| ▸ | AHCY | P23526 | 7/20 | 0.71 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | PI4KA | P42356 | 2/20 | 0.56 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.56 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.54 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2554197 | 1.00 | ADORA2A (0.71) | ADORA2AAHCYADORA1ALDH1A1PI4KA | |
| SCHEMBL16578129 | 1.00 | ADORA2A (0.71) | ADORA2AAHCYADORA1ALDH1A1PI4KA | |
| SCHEMBL16603993 | 0.87 | AHCY (0.85) | ADORA2AAHCYADORA1ALDH1A1PI4KA | |
| SCHEMBL14658528 | 0.87 | ADORA2A (0.67) | ADORA2AAHCYADORA1ALDH1A1PI4KA | |
| SCHEMBL18715786 | 0.87 | ADORA2A (0.67) | ADORA2AAHCYADORA1ALDH1A1PI4KA | |
| SCHEMBL2568602 | 0.87 | ADORA2A (0.69) | ADORA2AAHCYADORA1ALDH1A1PI4KA | |
| SCHEMBL14659290 | 0.87 | ADORA2A (0.69) | ADORA2AAHCYADORA1ALDH1A1PI4KA | |
| SCHEMBL14963614 | 0.85 | ADORA2A (0.76) | ADORA2AAHCYADORA1ALDH1A1PI4KA | |
| SCHEMBL13394189 | 0.85 | ADORA2A (0.76) | ADORA2AAHCYADORA1ALDH1A1PI4KA | |
| SCHEMBL10515035 | 0.84 | AHCY (0.67) | ADORA2AAHCYADORA1ALDH1A1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11166976-B2 | S-antigen transport inhibiting oligonucleotide polymers and methods | ALIGOS THERAPEUTICS, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200405743-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
| US-20170096441-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-04-06 | — | — | US | disclosed |
| US-9475832-B2 | Phosphonates with reduced toxicity for treatment of viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-10-25 | — | — | US | disclosed |
| US-20150080344-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-8846643-B2 | Phosphonates with reduced toxicity for treatment of viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2558466-A2 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | The Regents of the University of California (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20130029940-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-01-31 | — | — | US | disclosed |
| WO-2011130557-A2 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096441-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | POLRMT, PNP, MTAP | ADORA2A 1171/4885AHCY 727/4885ADORA1 1205/4885 |
| US-11166976-B2 | S-antigen transport inhibiting oligonucleotide polymers and methods | RNGTT, PHAX, HAVCR2 | ADORA2A 1563/4885AHCY 532/4885ADORA1 1419/4885 |
| US-20200405743-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | RNGTT, PHAX, HAVCR2 | ADORA2A 1563/4885AHCY 532/4885ADORA1 1419/4885 |
| US-20130029940-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | POLRMT, PNP, MTAP | ADORA2A 1171/4885AHCY 727/4885ADORA1 1205/4885 |
| US-20150080344-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | POLRMT, PNP, MTAP | ADORA2A 1171/4885AHCY 727/4885ADORA1 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.